2025 Q3 -tulosraportti
Vain PDF
23 päivää sitten
Tarjoustasot
Nordic Growth Market
Määrä
Osto
2 000
Myynti
Määrä
5 099
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | NON | NON | ||
| 999 | NON | AVA | ||
| 20 | AVA | AVA | ||
| 980 | AVA | ENS | ||
| 20 | ENS | ENS |
Ylin
1,775VWAP
Alin
1,56VaihtoMäärä
0 16 737
VWAP
Ylin
1,775Alin
1,56VaihtoMäärä
0 16 737
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 4.3.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 28.11. | |
| 2025 Q2 -tulosraportti | 29.8. | |
| 2025 Q1 -tulosraportti | 23.5. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 28.11.2024 |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·7.9.Anyone have any insight into this company? Is it unreasonable to believe that they will be profitable in 2026?
·2.12.The company is not burning money, so as soon as the results from the In vitro tests come, it will hopefully be a trigger.·2 päivää sittenAs previously announced, a blood bank in Norway has evaluated our transfusion product, Glycosorb® ABO (4 ml), for the preparation of low-titer blood group O platelet concentrate with good results. The results have recently been presented at a national transfusion congress in Norway. Apheresis platelet concentrate of blood group O contains anti-A/B antibodies (blood group-specific antibodies), and can be transfused to recipients of blood group A, B or AB, as long as the concentrate contains a low titer (level) of these anti-A/B antibodies. The method traditionally used to reduce anti-A/B antibodies from blood group O platelet concentrate involves treating the concentrate with centrifugation and diluting it with a buffer solution. The conclusion from the evaluation was that Glycosorb® ABO (4 ml) was more effective at lowering anti-A/B antibodies than the currently used method, resulted in lower activation of platelets, and that the procedure itself was easy to perform with our product. This confirms the experiences from NHS in the UK last year, where it was shown that anti-A/B antibody titers in platelet concentrate can be effectively reduced with Glycosorb® ABO (4ml). Platelet transfusions are primarily used in oncology, surgery, and hematology, where patients have an increased need for platelets to prevent or treat bleeding. It is estimated that approximately 2.4 million units of platelet concentrate are used annually in Europe. Of these, about 1 million units are apheresis platelets (edqm, 2016).
·15.8.When will the results from the in vitro tests come in? They have been excellent and the boundaries of what has been possible have been expanded more and more. silent for three months, flip or flop?- ·30.5.I have followed the company for over twenty years as I am from the area and now is the time to invest in the company. They have products under testing and if approved, large orders will flow in. At least that is my hope.
·6.8.How does the pipeline for new products look like? Should you buy this stock?·6.8.Since the company has historically underperformed, I don't think you need to rush into the stock. The positive is if they can maintain cost control. So probably the best risk/reward to buy in if/when they approach profitability. 
·22.1.I can accept all the arguments regarding the directed new issue except for the sky-high percentage discount in relation to the current price and the year's price, due to volatility in the share. If you have that view of the price setting, you should refrain from subscribing unless the intention is, as was the case with the previous directed issue, to stay and sell as long as you are in the black. That pushed the price down for 1.5 years. I hope I am wrong and we see more purchases from these investors.- ·7.1.What a nice development for the stock.10.1.10.1.why it is going up?
·31.1.If all goes well, Glycorex is on its way to gaining acceptance for its methods of purifying the blood. Think universal blood plasma. That is the main reason. The problem is and has been that Glycorex's management is not business-oriented, i.e. great company with great products with mediocare management. If we had someone like Ola Rollén, Melker Schörling, Gustaf Douglas who knows how to grow a company, it would have been reflected in the stock price.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
23 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·7.9.Anyone have any insight into this company? Is it unreasonable to believe that they will be profitable in 2026?·2.12.The company is not burning money, so as soon as the results from the In vitro tests come, it will hopefully be a trigger.·2 päivää sittenAs previously announced, a blood bank in Norway has evaluated our transfusion product, Glycosorb® ABO (4 ml), for the preparation of low-titer blood group O platelet concentrate with good results. The results have recently been presented at a national transfusion congress in Norway. Apheresis platelet concentrate of blood group O contains anti-A/B antibodies (blood group-specific antibodies), and can be transfused to recipients of blood group A, B or AB, as long as the concentrate contains a low titer (level) of these anti-A/B antibodies. The method traditionally used to reduce anti-A/B antibodies from blood group O platelet concentrate involves treating the concentrate with centrifugation and diluting it with a buffer solution. The conclusion from the evaluation was that Glycosorb® ABO (4 ml) was more effective at lowering anti-A/B antibodies than the currently used method, resulted in lower activation of platelets, and that the procedure itself was easy to perform with our product. This confirms the experiences from NHS in the UK last year, where it was shown that anti-A/B antibody titers in platelet concentrate can be effectively reduced with Glycosorb® ABO (4ml). Platelet transfusions are primarily used in oncology, surgery, and hematology, where patients have an increased need for platelets to prevent or treat bleeding. It is estimated that approximately 2.4 million units of platelet concentrate are used annually in Europe. Of these, about 1 million units are apheresis platelets (edqm, 2016).
- ·15.8.When will the results from the in vitro tests come in? They have been excellent and the boundaries of what has been possible have been expanded more and more. silent for three months, flip or flop?
- ·30.5.I have followed the company for over twenty years as I am from the area and now is the time to invest in the company. They have products under testing and if approved, large orders will flow in. At least that is my hope.·6.8.How does the pipeline for new products look like? Should you buy this stock?·6.8.Since the company has historically underperformed, I don't think you need to rush into the stock. The positive is if they can maintain cost control. So probably the best risk/reward to buy in if/when they approach profitability.
- ·22.1.I can accept all the arguments regarding the directed new issue except for the sky-high percentage discount in relation to the current price and the year's price, due to volatility in the share. If you have that view of the price setting, you should refrain from subscribing unless the intention is, as was the case with the previous directed issue, to stay and sell as long as you are in the black. That pushed the price down for 1.5 years. I hope I am wrong and we see more purchases from these investors.
- ·7.1.What a nice development for the stock.10.1.10.1.why it is going up?·31.1.If all goes well, Glycorex is on its way to gaining acceptance for its methods of purifying the blood. Think universal blood plasma. That is the main reason. The problem is and has been that Glycorex's management is not business-oriented, i.e. great company with great products with mediocare management. If we had someone like Ola Rollén, Melker Schörling, Gustaf Douglas who knows how to grow a company, it would have been reflected in the stock price.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nordic Growth Market
Määrä
Osto
2 000
Myynti
Määrä
5 099
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | NON | NON | ||
| 999 | NON | AVA | ||
| 20 | AVA | AVA | ||
| 980 | AVA | ENS | ||
| 20 | ENS | ENS |
Ylin
1,775VWAP
Alin
1,56VaihtoMäärä
0 16 737
VWAP
Ylin
1,775Alin
1,56VaihtoMäärä
0 16 737
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 4.3.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 28.11. | |
| 2025 Q2 -tulosraportti | 29.8. | |
| 2025 Q1 -tulosraportti | 23.5. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 28.11.2024 |
Datan lähde: Quartr, FactSet
2025 Q3 -tulosraportti
Vain PDF
23 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 4.3.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 28.11. | |
| 2025 Q2 -tulosraportti | 29.8. | |
| 2025 Q1 -tulosraportti | 23.5. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 28.11.2024 |
Datan lähde: Quartr, FactSet
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·7.9.Anyone have any insight into this company? Is it unreasonable to believe that they will be profitable in 2026?·2.12.The company is not burning money, so as soon as the results from the In vitro tests come, it will hopefully be a trigger.·2 päivää sittenAs previously announced, a blood bank in Norway has evaluated our transfusion product, Glycosorb® ABO (4 ml), for the preparation of low-titer blood group O platelet concentrate with good results. The results have recently been presented at a national transfusion congress in Norway. Apheresis platelet concentrate of blood group O contains anti-A/B antibodies (blood group-specific antibodies), and can be transfused to recipients of blood group A, B or AB, as long as the concentrate contains a low titer (level) of these anti-A/B antibodies. The method traditionally used to reduce anti-A/B antibodies from blood group O platelet concentrate involves treating the concentrate with centrifugation and diluting it with a buffer solution. The conclusion from the evaluation was that Glycosorb® ABO (4 ml) was more effective at lowering anti-A/B antibodies than the currently used method, resulted in lower activation of platelets, and that the procedure itself was easy to perform with our product. This confirms the experiences from NHS in the UK last year, where it was shown that anti-A/B antibody titers in platelet concentrate can be effectively reduced with Glycosorb® ABO (4ml). Platelet transfusions are primarily used in oncology, surgery, and hematology, where patients have an increased need for platelets to prevent or treat bleeding. It is estimated that approximately 2.4 million units of platelet concentrate are used annually in Europe. Of these, about 1 million units are apheresis platelets (edqm, 2016).
- ·15.8.When will the results from the in vitro tests come in? They have been excellent and the boundaries of what has been possible have been expanded more and more. silent for three months, flip or flop?
- ·30.5.I have followed the company for over twenty years as I am from the area and now is the time to invest in the company. They have products under testing and if approved, large orders will flow in. At least that is my hope.·6.8.How does the pipeline for new products look like? Should you buy this stock?·6.8.Since the company has historically underperformed, I don't think you need to rush into the stock. The positive is if they can maintain cost control. So probably the best risk/reward to buy in if/when they approach profitability.
- ·22.1.I can accept all the arguments regarding the directed new issue except for the sky-high percentage discount in relation to the current price and the year's price, due to volatility in the share. If you have that view of the price setting, you should refrain from subscribing unless the intention is, as was the case with the previous directed issue, to stay and sell as long as you are in the black. That pushed the price down for 1.5 years. I hope I am wrong and we see more purchases from these investors.
- ·7.1.What a nice development for the stock.10.1.10.1.why it is going up?·31.1.If all goes well, Glycorex is on its way to gaining acceptance for its methods of purifying the blood. Think universal blood plasma. That is the main reason. The problem is and has been that Glycorex's management is not business-oriented, i.e. great company with great products with mediocare management. If we had someone like Ola Rollén, Melker Schörling, Gustaf Douglas who knows how to grow a company, it would have been reflected in the stock price.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nordic Growth Market
Määrä
Osto
2 000
Myynti
Määrä
5 099
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | NON | NON | ||
| 999 | NON | AVA | ||
| 20 | AVA | AVA | ||
| 980 | AVA | ENS | ||
| 20 | ENS | ENS |
Ylin
1,775VWAP
Alin
1,56VaihtoMäärä
0 16 737
VWAP
Ylin
1,775Alin
1,56VaihtoMäärä
0 16 737
Välittäjätilasto
Dataa ei löytynyt